Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETRIEVE: Bortezomib Retreatment in Multiple Myeloma
NCT00431769Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2006
- Primary completion
- Feb 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Best Confirmed Response to Bortezomib Re-Treatment. Started Jun 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00431769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431769.